Return to Article Details
Lebrikizumab Confirms a Consistent Safety Profile in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis: Data From 11 Trials With Over 3000 Patient-Years of Exposure
Download
Download PDF